BioMarin Board Adds Two New Directors

Date Posted:
Jul 19, 2016

North Bay pharmaceutical company BioMarin has announced two new additions to its Board of Directors. Willard Dere, M.D., Professor of Internal Medicine at the University of Utah Health Sciences Center and former Senior Vice President in Research and Development at Amgen and Kathryn E. Falberg, former Chief Financial Officer of Jazz Pharmaceuticals and Amgen.

BioMarin CEO Jean-Jacques Bienaimé describes the new appointments as bringing “additional industry experience in drug development and finance to an already outstanding board,” going on to note that “I am confident they will make meaningful contributions to support BioMarin through a transformative period of growth, as we continue to develop therapies to meet the unmet medical needs of patients with rare genetic diseases.”

For more information visit the BioMarin website.